That's blameworthy. Congress routinely cedes what are essentially legislative powers to such agencies. It helps them dodge responsibility. IMHO it improperly transfers Article I powers to the Article II branch.
There are 2 possible reasons I see.
1) having to change the political leadership of it every 2 years (instead of 4) means it possibly wont be as effective.
2) as there is both a "lawmaking" and "enforcement" aspect to it, it makes sense for it to be under "one roof" so to speak, and it would probably be more problematic for the executive to cede that to congress than vice versa.
perhaps there are other reasons? and one can counter the above reasons?
You can take a look here: https://en.wikipedia.org/wiki/Party_divisions_of_United_Stat.... You'll notice that the individual chambers of congress change hands less often than the presidency.
Additionally, Congress has a high incumbency rate. Even in huge swing years like 2018, the makeup of Congress remains largely the same.
It directs the FDA to set these fees to raise a certain amount... but it lets the FDA decide how they want to do that. (There are other fees set in the law, but those arent the ones the article is complaining about.) They publish these fees in the federal register, and they become effective after a short while. This is part of the normal rule making process that the executive branch is responsible for... these rules fill in the blanks in legislation passed by congress.
The FDA published these prices yesterday on Dec 29th. https://www.federalregister.gov/documents/2020/12/29/2020-28...
Theres nothing in the CARES act that requires the FDA charge distilleries.